Revance Therapeutics Inc to Post Q2 2019 Earnings of ($0.86) Per Share, Piper Jaffray Companies Forecasts (RVNC)

Revance Therapeutics Inc (NASDAQ:RVNC) – Analysts at Piper Jaffray Companies increased their Q2 2019 earnings estimates for shares of Revance Therapeutics in a research report issued on Wednesday, May 8th. Piper Jaffray Companies analyst D. Amsellem now expects that the biopharmaceutical company will earn ($0.86) per share for the quarter, up from their previous estimate of ($0.89). Piper Jaffray Companies also issued estimates for Revance Therapeutics’ Q3 2019 earnings at ($0.98) EPS, Q4 2019 earnings at ($1.09) EPS, Q1 2020 earnings at ($1.09) EPS, Q2 2020 earnings at ($1.00) EPS, Q3 2020 earnings at ($0.72) EPS, Q4 2020 earnings at ($0.40) EPS, FY2020 earnings at ($3.21) EPS, FY2021 earnings at ($0.94) EPS, FY2022 earnings at $2.52 EPS and FY2023 earnings at $3.67 EPS.

Several other analysts have also recently commented on RVNC. Zacks Investment Research cut shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. ValuEngine upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Mizuho reiterated a “buy” rating and set a $37.00 target price on shares of Revance Therapeutics in a research report on Wednesday, April 24th. Wells Fargo & Co assumed coverage on shares of Revance Therapeutics in a research report on Friday, February 15th. They set a “market perform” rating and a $17.83 target price for the company. Finally, HC Wainwright assumed coverage on shares of Revance Therapeutics in a research report on Thursday, February 14th. They set a “buy” rating and a $25.00 target price for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $33.73.

Shares of Revance Therapeutics stock opened at $12.63 on Monday. The firm has a market cap of $556.10 million, a price-to-earnings ratio of -3.21 and a beta of 0.75. Revance Therapeutics has a 52 week low of $10.51 and a 52 week high of $32.45.

Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.02). The business had revenue of $0.28 million for the quarter, compared to the consensus estimate of $1.85 million. Revance Therapeutics had a negative net margin of 3,745.97% and a negative return on equity of 79.71%.

In other news, CEO L Daniel Browne sold 5,446 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $17.68, for a total value of $96,285.28. Following the completion of the transaction, the chief executive officer now owns 174,389 shares of the company’s stock, valued at approximately $3,083,197.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 17,557 shares of company stock valued at $284,112 in the last three months. 5.20% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in RVNC. BlackRock Inc. grew its holdings in shares of Revance Therapeutics by 10.7% in the 1st quarter. BlackRock Inc. now owns 3,550,138 shares of the biopharmaceutical company’s stock valued at $55,951,000 after buying an additional 343,538 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Revance Therapeutics by 197.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 225,708 shares of the biopharmaceutical company’s stock valued at $4,543,000 after buying an additional 149,952 shares during the period. Deutsche Bank AG grew its holdings in shares of Revance Therapeutics by 51.1% in the 4th quarter. Deutsche Bank AG now owns 331,820 shares of the biopharmaceutical company’s stock valued at $6,678,000 after buying an additional 112,193 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Revance Therapeutics by 2.4% in the 1st quarter. JPMorgan Chase & Co. now owns 3,897,870 shares of the biopharmaceutical company’s stock valued at $61,431,000 after buying an additional 92,811 shares during the period. Finally, Rice Hall James & Associates LLC grew its holdings in shares of Revance Therapeutics by 252.7% in the 1st quarter. Rice Hall James & Associates LLC now owns 117,068 shares of the biopharmaceutical company’s stock valued at $1,845,000 after buying an additional 83,875 shares during the period. 79.83% of the stock is owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

Further Reading: How to trade on quiet period expirations

Earnings History and Estimates for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.